Doxil dosage should be reduced in patients with impaired hepatic function. Prior to Doxil administration, evaluation of hepatic function is recommended using conventional clinical laboratory tests such as SGOT, SGPT, alkaline phosphatase and bilirubin. Carcinogenesis, Mutagenesis, Impairment of Fertility Secondary acute myelogenous leukemia has been reported in patients treated with topoisomerase II inhibitors, including anthracyclines. Although no studies have been conducted with Doxil , doxorubicin HCl and related compounds have been shown to have mutagenic and carcinogenic properties when tested in experimental models. The possible adverse effects on fertility in males and females in humans or experimental animals have not been adequately evaluated.
Most adverse events are manageable with dose reductions or delays.
Laboratory Tests Complete blood counts, including platelet counts, should be obtained frequently and at a minimum prior to each dose of Doxil. No formal drug interaction studies have been conducted with Doxil . Until specific compatibility data are available, it is not recommended that Doxil be mixed with other drugs. Doxil may interact with the conventional formulation of doxorubicin HCl. It is not known whether this drug is excreted in human milk.